英[ɪnˈelɪdʒəbl] 美[ɪnˈɛlɪdʒəbəl] 是什么意思 adj. 无入选资格的,不合格的;无被选权; 英英释义 ineligible[ in'elidʒəbl ] adj. not eligible "ineligible to vote"; "ineligible for retirement benefits" ...
In multivariable analyses, 5-year overall survival was not significantly different in long-term quitters in the hospital cohort versus in those who met USPSTF criteria (HR 1·02; 95% CI 0·94–1·10; p=0·72) after adjustment of significant variables in univariable analysis (figure 1A). ...
Trifluridine/tipiracil (TAS-102; Lonsurf), when used in combination with bevacizumab (Avastin), led to an improvement in overall survival (OS) over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not eligible for stand...
There was an excess of pneumonia, with 11% grade 3 pneumonia in the daratumumab-plus-VMP arm versus 4% in the VMP arm.There is an [ongoing] study, which looks at daratumumab in combination with RVd in patients who are getting ASCT. For patients who are not eligible for ASCT, there is...
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer. Docetaxel and vinorelbine have demonstrated efficacy in the treatment of metastatic breast cancer (MBC). This prospective feasibility study compared the ef... Carlo,Palmieri,Constantine,... - 《Oncologist》 被引量...
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years ...
Bortezomib (Velcade)-melphalan-prednisone (VMP) versus Velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: Which is the best partner for Velcade: An alkylating or an immunomodulator agent? Blood 2008; 112 (abstract [651]). Palumbo A, Bringhen S, Rossi D, Magar...
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). J Clin Oncol. 2024;42(suppl 16):7500. doi:10.1200/JCO.2024.42.16_suppl.7500. 2. Facon T, Dimopoulos M-...
Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study,Australasian Leukaemia & Lymphoma Group,Interventional,Phase 1/Phase 2
The combination therapy showed superior progression-free survival and MRD-negativity rates, with a 60-month PFS rate of 63.2% versus 45.2% for VRd alone. SHOW MORE The CHMP has recommended the EU approval of isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple m...